The CCND1 c.870G > A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Niels Weinhold, David C. Johnson, Daniel Chubb, Bowang Chen, Asta Försti, Fay J. Hosking, Peter Broderick, Yussanne P. Ma, Sara E. Dobbins, Dirk Hose, Brian A. Walker, Faith E. Davies, Martin F. Kaiser, Ni L. Li, Walter A. Gregory, Graham H. Jackson, Mathias Witzens-Harig, Kai Neben, Per Hoffmann, Markus M. NoethenThomas W. Muehleisen, Lewin Eisele, Fiona M. Ross, Anna Jauch, Hartmut Goldschmidt, Richard S. Houlston, Gareth J. Morgan, Kari Hemminki

Research output: Contribution to journalArticlepeer-review

78 Citations (SciVal)


A number of specific chromosomal abnormalities define the subgroups of multiple myeloma. In a meta-analysis of two genome-wide association studies of multiple myeloma including a total of 1,661 affected individuals, we investigated risk for developing a specific tumor karyotype. The t(11;14)(q13;q32) translocation in which CCND1 is placed under the control of the immunoglobulin heavy chain enhancer was strongly associated with the CCND1 c.870G>A polymorphism (P = 7.96 x 10(-11)). These results provide a model in which a constitutive genetic factor is associated with risk of a specific chromosomal translocation.
Original languageEnglish
Pages (from-to)522-525
JournalNature Genetics
Issue number5
Publication statusPublished - 2013

Subject classification (UKÄ)

  • Public Health, Global Health, Social Medicine and Epidemiology


Dive into the research topics of 'The CCND1 c.870G > A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma'. Together they form a unique fingerprint.

Cite this